1
Nicholas S Bodor: Pharmaceutical formulations for parenteral use. University of Florida, Mary Katherine Baumeister, June 18, 1991: US05024998 (105 worldwide citation)

Aqueous parenteral solutions of drugs which are insoluble or only sparingly soluble in water and/or which are unstable in water, combined with cyclodextrin selected from the group consisting of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of .beta.- and .gamma.-cyclod ...


2
Nicholas S Bodor: Pharmaceutical formulations for parenteral use. University of Florida, Mary Katherine Baumeister, Dennis P Clarke, January 8, 1991: US04983586 (80 worldwide citation)

Aqueous parenteral solutions of drugs which are insoluble or only sparingly soluble in water and/or which are unstable in water, combined with hydroxypropyl-.beta.-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or o ...


3
Nicholas S Bodor: Orally active heparin salts containing multivalent cationic units. Mary Katherine Baumeister, October 27, 1987: US04703042 (65 worldwide citation)

The invention provides novel orally active salts of the formula ##STR1## in which .circle. is the skeleton of a polyol, n is the number of OH's in the polyol (3 to 24); p is .gtoreq.3 and .ltoreq.n; r is the available valence of the heparin unit and .gtoreq.3 and .ltoreq.7; sr is equal to pv; and R. ...


4
Nicholas S Bodor: Brain-enhanced delivery of neuroactive peptides by sequential metabolism. University of Florida, Burns Doane Swecker & Mathis L, April 29, 1997: US05624894 (65 worldwide citation)

The invention provides novel peptide derivatives which are designed to deliver pharmacologically active peptides into the central nervous system by sequential metabolism. The peptide is placed in a molecular environment which disguises its peptide nature and provides biolabile, lipophilic functions ...


5
Nicholas S Bodor: Brain-specific drug delivery. University of Florida, Dennis P Clarke, September 10, 1985: US04540564 (64 worldwide citation)

The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:


6
Nicholas S Bodor: Soft steroids having anti-inflammatory activity. Otsuka Pharmaceutical, Burns Doane Swecker & Mathis, December 1, 1987: US04710495 (54 worldwide citation)

Novel soft steroid anti-inflammatory agents, said agents being esters or thioesters of 17.alpha.-alkoxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-carboxylic acids, pharmaceutical compositions containing said agents, novel chemical intermediates useful in the preparation of said agents and methods ...


7

8
Nicholas S Bodor: Soft steroids having anti-inflammatory activity. Nicholas S Bodor, Burns Doane Swecker & Mathis, February 26, 1991: US04996335 (47 worldwide citation)

The invention provides novel soft steroidal anti-inflammatory agents, pharmaceutical compositions containing said agents, and methods of administering same to mammals in the treatment of inflammation. Preferred compounds of the invention include haloalkyl 17.alpha.-alkoxycarbonyloxy-11.beta.-hydroxy ...


9
Nicholas S Bodor: Targeted drug delivery via phosphonate derivatives. University of Florida, Burns Doane Swecker & Mathis, May 9, 1995: US05413996 (45 worldwide citation)

The invention provides compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein [D] is the residue of a drug having a reactive functional group, said functional group being attached, directly or through a bridging group, via an oxygen-phosphorus bond to the phosphorus ...


10
Nicholas S Bodor: Brain-specific drug delivery. University of Florida, Dennis P Clarke, October 30, 1984: US04479932 (45 worldwide citation)

Centrally acting drug species are site-specifically/sustainedly delivered to the brain by administering to a patient in need of such treatment a therapeutically effective amount of the target drug species [D] tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropy ...



Click the thumbnails below to visualize the patent trend.